These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3144528)

  • 1. The penetration of fleroxacin into intra-abdominal abscesses.
    Youngs DJ; Tudor RG; Yoshioka K; Keighley MR
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():115-8. PubMed ID: 3144528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the penetration of two quinolones into intra-abdominal abscess.
    Tudor RG; Youngs DJ; Yoshioka K; Burdon DW; Keighley MR
    Arch Surg; 1988 Dec; 123(12):1487-90. PubMed ID: 3142444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model.
    Leibovitz E; Keren G; Shabtai M; Barzilai A; Rubinstein E
    J Antimicrob Chemother; 1989 Sep; 24(3):375-85. PubMed ID: 2509411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penetration of fleroxacin into maxillary sinus mucosa and palatine tonsil.
    Baba S; Mori Y; Maruo T
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():195-7. PubMed ID: 3144538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The penetration of aztreonam, a monobactam antibiotic, into intra-abdominal abscesses.
    Youngs DJ; Burdon DW; Keighley MR
    J Antimicrob Chemother; 1989 Sep; 24(3):425-9. PubMed ID: 2681121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
    Sorgel F; Metz R; Naber K; Seelmann R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
    Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli.
    Hof H; Fabrig J
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():123-7. PubMed ID: 3144530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
    Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration of ciprofloxacin and fleroxacin into biliary tract.
    Edmiston CE; Suarez EC; Walker AP; Demeure MP; Frantzides CT; Schulte WJ; Wilson SD
    Antimicrob Agents Chemother; 1996 Mar; 40(3):787-91. PubMed ID: 8851613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single and multiple dose pharmacokinetics of fleroxacin.
    Weidekamm E; Portmann R; Partos C; Dell D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
    Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection.
    Kosmidis J; Gargalianos P; Adamis G; Petropoulou D; Makris D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():219-21. PubMed ID: 3144541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of fleroxacin against experimental pneumonia in mice.
    Niki Y; Watanabe M; Tasaka Y; Umeki S; Soejima R
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():129-31. PubMed ID: 3144531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
    Fu KP; Vince T; Bloom R; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(8):493-6. PubMed ID: 3322752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of ciprofloxacin in the treatment of experimental intra-abdominal abscesses in mice.
    Esposito S
    Clin Ther; 1989; 11(1):32-7. PubMed ID: 2720726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Good penetration of moxifloxacin into human abscesses.
    Sauermann R; Karch R; Kjellsson MC; Feurstein T; Püspök A; Langenberger H; Böhmdorfer M; Jäger W; Zeitlinger M
    Pharmacology; 2012; 90(3-4):146-50. PubMed ID: 22868236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
    Bauernfeind A; Eberlein E; Hörl G
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():81-9. PubMed ID: 3144553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.
    Shah PM; Sammann A; Schäfer V; Seczendi M; Knothe H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():209-13. PubMed ID: 3144539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.